Malignant News and Research

RSS

MYCN amplification can serve as a favorable prognostic indicator for neuroblastoma

Neuroblastoma, a malignant tumor that primarily affects infants and young children, is a leading cause of death for children with cancer. When amplification of the MYCN oncogene is found in the tumor, it usually indicates an aggressive tumor with rapid progression of the disease and a poor outcome. Thus MYCN amplification has come to be used as a prognostic indicator.

12 Aug 2011

Cancer-causing fusion protein works by silencing tumor suppressor gene IL-2Rγ

Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain.

10 Aug 2011

Health Canada approves Boston Scientific's WallFlex Biliary RX Fully Covered Stent

Boston Scientific Corporation's WallFlex Biliary RX Fully Covered Stent has received Health Canada approval for the treatment of benign biliary strictures, which supplements its current indication for management of malignant biliary strictures.

10 Aug 2011

Researchers discover gene variant linked to meningiomas

The causes of brain tumours have been hard to discern in most cases. But Umeå researchers have previously identified an inherited predisposition for brain tumours, and now, in an international collaboration, they have also discovered a genetic variation that increases the risk of a certain type of brain tumour, called meningiomas.

8 Aug 2011

New insights into cancer-induced intussusceptive angiogenesis

Researchers have gained a new understanding of the way in which growing tumors are fed and how this growth can be slowed via angiogenesis inhibitors that eliminate the blood supply to tumors. This represents a step forward towards developing new anti-cancer drug therapies.

8 Aug 2011

Specific microRNA cluster could play a key role in retinoblastoma development

New research from a team including several Carnegie scientists demonstrates that a specific small segment of RNA could play a key role in the growth of a type of malignant childhood eye tumor called retinoblastoma.

5 Aug 2011

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

YM BioSciences Inc., today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011.

5 Aug 2011

Micromet second quarter total revenues increase to $7.1 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Innovative delivery systems and methods to treat breast cancer

In their lifetime, women have more than a 12 percent risk of being diagnosed with breast cancer. 1 This week, research on novel approaches to breast cancer treatment is being presented at the Era of Hope (EOH) conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP).

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

New insights into genesis and development of Sézary syndrome

Scientists at Charité - Universitätsmedizin Berlin, Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, the Max-Planck-Institut für Molekulare Genetik Berlin, and four other German institutes succeeded in proving a specific gene loss in a certain human lymphoma, the genesis of which is largely unexplained to date.

3 Aug 2011

Cancer Research UK honors Nottingham scientist with prestigious award

A University of Nottingham scientist who uses fruit flies to study the genetics of cancer has won a prestigious award from Cancer Research UK.

3 Aug 2011

Scientists reveal genetic region that increases risk of meningioma

Cancer Research UK funded scientists have conducted the first whole-genome scan of the brain tumour meningioma and revealed a genetic region that increases the risk of developing the disease, according to research published in Nature Genetics today.

1 Aug 2011

Researchers reveal molecular mechanisms responsible for organizing intestinal epithelium

How do cells know where to position themselves and where to accumulate in order to carry out their functions correctly within each organ? Researchers with the Colorectal Cancer Lab at IRB Barcelona have revealed the molecular mechanisms responsible for organizing the intestinal epithelium into distinct comportments, defined by frontiers or territories.

1 Aug 2011

Skin cancer vaccine on the way: Cancer expert Prof Ian Frazer

In a major medical breakthrough, cancer expert Prof Ian Frazer is on the verge of developing a vaccine against skin cancer within a year. The former ‘Australian of the Year’ and creator of the world's first cervical cancer vaccine, Gardasil, has developed a world-first strategy to combat the insidious disease that affects two out of three Australians.

31 Jul 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

Breast cancer survival and lymph nodes

A large new study has found that a lymph node-sparing test hailed as revolutionary for its conservative approach does not lead to longer survival times for women undergoing lumpectomies whose early-stage breast cancer has spread microscopically.

27 Jul 2011

MR-guided focused ultrasound prior to radiation therapy could treat cancer

Hypoxic tumor cells usually resist radiation and chemotherapy, making them a key challenge in treating cancer. Researcher Xin Chen, Ph.D. believes that MR-guided focused ultrasound could reduce this problem, benefiting patients with malignant solid tumors in areas such as the liver, prostate and breast.

27 Jul 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.

26 Jul 2011

Tumor marker, endoscopic ultrasound more likely to detect stage 1 pancreatic cancer

Researchers from New England report in a new study that using a tumor marker, serum CA 19-9, combined with an endoscopic ultrasound if the tumor marker is elevated, is more likely to detect stage 1 pancreatic cancer in a high-risk population than by using the standard means of detection.

26 Jul 2011